Xeris Biopharma Holdings, Inc. (XERS)
NASDAQ: XERS · Real-Time Price · USD
10.48
+0.29 (2.85%)
Oct 9, 2026, 4:00 PM EDT - Market closed
Xeris Biopharma Holdings Employees
Xeris Biopharma Holdings had 435 employees as of December 31, 2025. The number of employees increased by 41 or 10.41% compared to the previous year. That makes Xeris Biopharma Holdings the 21,172nd largest employer in the world and 2,786th in the United States.
Employees
435
Change (1Y)
41
Growth (1Y)
10.41%
Revenue / Employee
$771,067
Profits / Employee
-$39,460
Market Cap
1.91B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 435 | 41 | 10.41% |
| Dec 31, 2024 | 394 | 17 | 4.51% |
| Dec 31, 2023 | 377 | 22 | 6.20% |
| Dec 31, 2022 | 355 | 61 | 20.75% |
| Dec 31, 2021 | 294 | 114 | 63.33% |
| Sep 30, 2021 | 325 | 153 | 88.95% |
| Jun 30, 2021 | 253 | 65 | 34.57% |
| Mar 31, 2021 | 209 | 10 | 5.03% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Sep 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jun 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Bausch Health Companies | 20,300 |
| Perrigo Company | 8,100 |
| Trulieve Cannabis | 5,000 |
| Phibro Animal Health | 2,605 |
| Alvotech | 1,279 |
| ANI Pharmaceuticals | 970 |
| Prestige Consumer Healthcare | 890 |
| Supernus Pharmaceuticals | 778 |
XERS News
- 4 days ago - Xeris Biopharma price target raised to $14 from $12 at Barclays - TheFly
- 8 days ago - Xeris Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - Business Wire
- 11 days ago - Lundbeck expresses interest in buying Xeris, Bloomberg News reports - Reuters
- 11 days ago - Lundbeck exploring acquisition of Xeris, Bloomberg reports - TheFly
- 11 days ago - Xeris Biopharma tells Bloomberg ‘not for sale’ - TheFly
- 26 days ago - Xeris Biopharma Holdings Transcript: H.C. Wainwright 28th Annual Global Investment Conference - Transcripts
- 4 weeks ago - Xeris Biopharma price target raised to $16 from $12 at Leerink - TheFly
- 4 weeks ago - Xeris Biopharma price target raised to $16 from $12 at Leerink - TheFly